A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese

NCT06039826 · Completed

Last updated 2026-05-28

This clinical trial is testing the effects of the drug LY3437943 on postmenopausal women who are overweight or obese to understand how the body processes it.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) basic-science study

Participants 46 people

Who can join Ages 40–60 · female only

Timeline Started 2023-09 · est. completion 2024-07

Where 2 sites · United States

What this study is testing ClinicalTrials.gov NCT06039826 ↗

Description as written by the study sponsor.

The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of combined oral contraceptive (COC) ethinyl estradiol and drospirenone in the blood stream in postmenopausal female participants who are overweight or obese. The safety and tolerability of LY3437943 when administered with COC will also be evaluated. This study will last up to approximately 29 weeks for each participant.

Treatments tested

LY3437943 Drug

Administered SC.
Ethinyl Estradiol Drug

Administered orally
Drospirenone Drug

Administered orally

Main thing measured	Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time zero to 24 Hours Postdose (AUC0-24) of Ethinyl Estradiol
Sponsor	Eli Lilly and Company
Conditions studied	Overweight
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06039826 ↗